Apolo, Andrea B http://orcid.org/0000-0001-9409-1836
Ellerton, John A
Infante, Jeffrey R
Agrawal, Manish
Gordon, Michael S
Aljumaily, Raid
Gourdin, Theodore
Dirix, Luc
Lee, Keun-Wook
Taylor, Matthew H
Schöffski, Patrick
Wang, Ding
Ravaud, Alain http://orcid.org/0000-0001-9455-6744
Manitz, Juliane
Pennock, Gregory
Ruisi, Mary
Gulley, James L http://orcid.org/0000-0002-6569-2912
Patel, Manish R
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
https://doi.org/10.1136/jitc-2020-001064
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246
Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
https://doi.org/10.1136/jitc-2021-002998
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427
296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0296
540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2021-sitc2021.540
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
https://doi.org/10.1136/annrheumdis-2018-213777
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
https://doi.org/10.1200/jco.2023.41.16_suppl.4515
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
https://doi.org/10.1007/s10147-021-02067-8
665 JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma
https://doi.org/10.1136/jitc-2022-sitc2022.0665
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.
https://doi.org/10.1200/jco.2024.42.4_suppl.581
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.4516
Application of statistical machine learning in biomarker selection
https://doi.org/10.1038/s41598-023-45323-9
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
https://doi.org/10.1200/jco.22.01792
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
https://doi.org/10.1200/jco.2024.42.4_suppl.600
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
https://doi.org/10.1200/jco.2023.41.6_suppl.508
Funding for this research was provided by:
Pfizer
Merck KGaA